OB/GYN Clinical Alert – March 1, 2011
March 1, 2011
View Issues
-
Prediction of Intra-amniotic Inflammation
Although the relationship between intrauterine infection and preterm labor (PTL) has been addressed in previous OB/GYN Clinical Alerts, I cannot pass up the opportunity to review a recent paper that sheds new light on a rational approach to PTL. -
A New Clinical Entity for Ovarian Cancer
Ova-301 was a large (n = 672), open-label phase III trial comparing pegylated liposomal doxorubicin (PLD) to combination PLD and trabectedin (PT) in women with recurrent ovarian cancer. The trial's overall population was previously reported and demonstrated a significant impact on PFS, without a significant improvement in OS. -
Shoulder Dystocia
Despite the important progress that has been made in obstetrics, in general, over the last 20 years, shoulder dystocia remains an enigma. Given the rising rate of maternal obesity and gestational diabetes, it is unlikely that the rate of this dangerous complication will be lowered in the near future. -
Will Ovarian Cancer Screening Really Impact Mortality?
Recent investigation into the molecular pathogenesis of epithelial ovarian cancer has implicated two dominant phenotypes. -
Special Feature: Oral Contraceptive Use in Obese Women
Obesity is a growing problem in the united states. the pun would be funny were it not for the adverse influence that the obesity epidemic has had on health care outcomes. -
Pharmacology Watch: Escitalopram for Menopausal Hot Flashes
In this issue: Escitalopram for menopausal hot flashes, rifaximin for IBS without constipation, herpes zoster vaccination, antiepileptics drugs and fracture risk, and FDA Actions. -
Clinical Briefs in Primary Care supplement